Dominant B-cell epitopes from cancer / stem cell antigen SOC2 recognized by serum samples from cancer patients
Date
2014-08-30Source Title
American Journal of Clinical and Experimental Immunology
Print ISSN
2164-7712
Publisher
AJCEI
Volume
3
Issue
2
Pages
84 - 90
Language
English
Type
ArticleItem Usage Stats
62
views
views
16
downloads
downloads
Abstract
Human sex determining region Y-box 2 (SOX2) is an important transcriptional factor involved in the pluripotency
and stemness of human embryonic stem cells. SOX2 plays important roles in maintaining cancer stem cell activities
of melanoma and cancers of the brain, prostate, breast, and lung. SOX2 is also a lineage survival oncogene
for squamous cell carcinoma of the lung and esophagus. Spontaneous cellular and humoral immune responses
against SOX2 present in cancer patients classify it as a tumor-associated antigen (TAA) shared by lung cancer, glioblastoma,
and prostate cancer among others. In this study, B-cell epitopes were predicted using computer-assisted
algorithms. Synthetic peptides based on the prediction were screened for recognition by serum samples from cancer
patients using ELISA. Two dominant B-cell epitopes, SOX2:52-87 and SOX2:98-124 were identified. Prostate
cancer, glioblastoma and lung cancer serum samples that recognized the above SOX2 epitopes also recognized
the full-length protein based on Western blot. These B-cell epitopes may be used in assessing humoral immune
responses against SOX2 in cancer immunotherapy and stem cell-related transplantation.